Fluorescent Nucleic Acid-Functionalized Nanoparticles for Drug Delivery and Theranostics

The chemical approach used to attach fluorescent oligonucleotides to nanoparticle surfaces determines loading density, orientation, stability in biological media, and whether the nucleic acid retains its intended function (hybridization, enzymatic activity, aptamer binding). Four principal conjugation strategies are used: gold-thiol chemistry, covalent amide or click-based coupling, electrostatic adsorption, and biotin-streptavidin bridging. Each approach produces different surface densities, colloidal stabilities, and nuclease resistance profiles.

Gold-thiol chemistry is the most established method for attaching DNA to gold nanoparticles, exploiting the spontaneous formation of Au-S bonds between thiol-modified oligonucleotides and the gold surface. Oligonucleotides are synthesized with a 5' or 3' terminal thiol modifier (protected as a disulfide or trityl group), deprotected before conjugation, and incubated with citrate-stabilized gold nanoparticles. The salt-aging method, in which NaCl is gradually added to screen electrostatic repulsion between DNA strands, achieves high-density loading with ~100-200 oligonucleotides per 13-15 nm gold nanoparticle. For silica, polymeric, or liposomal nanoparticles, covalent coupling through amine-NHS ester chemistry or azide-alkyne click chemistry is preferred. Electrostatic adsorption of nucleic acids onto cationic nanoparticle surfaces (polyethylenimine, chitosan, cationic liposomes) is simpler but produces less stable conjugates and less predictable nucleic acid orientation.

Fluorophore Placement on Nanoparticle-Conjugated Oligonucleotides

The position of the fluorescent label on the oligonucleotide relative to the nanoparticle surface significantly affects signal. When the fluorophore is positioned at the nanoparticle-distal terminus (the end farthest from the NP surface), it experiences minimal quenching and maximum solvent exposure, producing strong fluorescence. When positioned at the nanoparticle-proximal terminus, the dye may be quenched by the gold surface through nanometal surface energy transfer (NSET) or by surface plasmon resonance effects. This distance-dependent quenching has been exploited to build "nano-flare" sensors where target binding displaces the fluorophore away from the gold surface, restoring fluorescence. For general tracking applications, distal labeling with a spacer (C6 or C12 linker) produces the strongest and most consistent signal.

Spherical nucleic acids (SNAs) are three-dimensional arrangements of densely packed, radially oriented oligonucleotides on a spherical nanoparticle core. First developed on gold nanoparticles, SNAs exhibit properties distinct from linear nucleic acids: they enter cells without transfection reagents through class A scavenger receptor-mediated endocytosis, resist nuclease degradation due to steric hindrance from the dense shell, and show cooperative binding behavior that enhances target affinity. Fluorescent labeling of the SNA shell enables direct visualization of these unique cellular interactions.

Gold nanoparticle-based SNAs are typically prepared by salt-aging thiol-modified oligonucleotides onto 10-50 nm gold cores. The resulting conjugates have a characteristic plasmon resonance peak that shifts predictably with oligonucleotide loading and can be used to estimate surface density. Fluorescent labels (FAM, Cy3, Cy5) are incorporated at the distal terminus of the DNA strands during synthesis. At high loading densities, fluorophore spacing on the SNA surface can be as close as 3-5 nm, raising the possibility of fluorophore-fluorophore interactions or self-quenching. Dye spacing should be maximized by using a mixed-monolayer approach where only a fraction (25-50%) of the strands carry a fluorophore, with the remainder being unlabeled oligonucleotides. This preserves high overall nucleic acid density for cellular uptake while maintaining individual fluorophore brightness.

The cellular internalization pathway of nucleic acid-nanoparticle conjugates determines their ultimate intracellular fate: lysosomal degradation, endosomal escape and cytosolic delivery, or recycling to the cell surface. Fluorescently labeled oligonucleotides on the nanoparticle surface provide a direct readout of each stage when combined with compartment-specific markers and appropriate imaging or flow cytometry protocols.

Distinguishing Surface-Bound from Internalized Nanoparticles

A common challenge in cellular uptake studies is distinguishing nanoparticles that are merely adsorbed to the cell surface from those that have been truly internalized. For gold nanoparticle-based systems, the distance-dependent quenching of fluorophores by the gold core provides a built-in discrimination mechanism: surface-adsorbed nanoparticles show weaker fluorescence because most fluorophores are oriented toward the extracellular space, while internalized nanoparticles in the crowded endosomal environment may show altered fluorescence due to local pH changes and molecular crowding. More definitive discrimination uses trypan blue quenching, where the membrane-impermeable quencher extinguishes fluorescence from extracellular nanoparticles but not internalized ones. For non-gold nanoparticles, acid-wash protocols or protease treatment (removing surface-exposed, membrane protein-adsorbed nanoparticles) followed by fluorescence quantification can distinguish internalized from surface-bound material.

Endosomal Escape Detection

Measuring endosomal escape is critical for nucleic acid therapeutics because cargo trapped in endosomes cannot access cytoplasmic or nuclear targets. Fluorescence colocalization with endosomal markers (EEA1 for early endosomes, LAMP1 for late endosomes/lysosomes) using spectrally distinct fluorophores quantifies the fraction of nanoparticles in each compartment. A shift from punctate (endosomal) to diffuse (cytosolic) fluorescence over time, when combined with a fluorescent readout of nucleic acid function (e.g., GFP knockdown for siRNA payloads), provides complementary evidence for endosomal escape and payload release.

Stimuli-responsive nucleic acid-nanoparticle systems release their therapeutic cargo or expose active nucleic acid sequences in response to specific biological cues: low endosomal pH, elevated glutathione (GSH) in the cytoplasm, ATP concentration, or tumor-associated enzymes. Fluorescent labels integrated into the responsive architecture report the release event in real time through changes in intensity, FRET ratio, or spectral shift.

pH-Responsive Systems

The pH gradient from the extracellular space (pH ~7.4) to early endosomes (pH ~6.0-6.5) to late endosomes/lysosomes (pH ~4.5-5.0) provides a natural trigger for cargo release. pH-responsive DNA structures, such as i-motifs (cytosine-rich sequences that fold at acidic pH into quadruplex structures) or triplex-forming oligonucleotides, undergo conformational changes at specific pH thresholds. When these structures are integrated into the nanoparticle shell and labeled with a FRET pair, the pH-induced conformational change alters the donor-acceptor distance and the FRET ratio. A FAM/TAMRA pair on an i-motif-functionalized nanoparticle, for example, produces a green-to-red ratio shift as the i-motif folds at pH below 6.5, reporting endosomal acidification.

Glutathione-Responsive Disulfide Cleavage

Intracellular glutathione concentrations (1-10 mM) are 100- to 1,000-fold higher than extracellular concentrations (2-20 microM). Disulfide-linked oligonucleotides on nanoparticle surfaces are stable in the extracellular environment but are cleaved in the reducing intracellular environment. By attaching the fluorophore-labeled therapeutic oligonucleotide to the nanoparticle through a disulfide linker, the release of the oligonucleotide can be monitored by the appearance of free-fluorophore fluorescence (no longer quenched by the nanoparticle) or by separation of a FRET donor-acceptor pair where one component remains on the nanoparticle and the other is released.

Theranostic nucleic acid-nanoparticle platforms co-localize imaging and therapeutic functions on a single nanoscale carrier, enabling real-time monitoring of drug delivery, verification of target engagement, and assessment of treatment response without separate imaging and therapeutic administrations. Fluorescent nucleic acids serve as the imaging component because they can be detected with standard fluorescence microscopy, in vivo imaging systems, or flow cytometry, while the nanoparticle core or co-loaded cargo provides the therapeutic function.

A representative theranostic architecture combines a gold nanorod core (photothermal therapy) with a Cy5-labeled DNA oligonucleotide shell (fluorescence imaging) and a doxorubicin payload intercalated into GC-rich duplex regions of the DNA shell (chemotherapy). Near-infrared irradiation of the gold nanorods generates localized heat for photothermal ablation while simultaneously denaturing the DNA duplex, releasing doxorubicin. The Cy5 fluorescence, initially quenched by proximity to the gold nanorod surface, increases as the DNA strands are released, providing a real-time fluorescent readout of the photothermal drug release process. This single-construct, dual-readout approach exemplifies the theranostic paradigm.

Tracking the biodistribution of nucleic acid-nanoparticle therapeutics in animal models is essential for pharmacokinetic characterization and safety evaluation. Fluorescently labeled oligonucleotides on the nanoparticle surface enable whole-animal fluorescence imaging, ex vivo organ imaging, and tissue section microscopy to map where the nanoparticles accumulate, how long they persist, and whether they reach target tissues.

For in vivo fluorescence imaging, far-red and near-infrared fluorophores (Cy5, Cy5.5, Cy7) are preferred because tissue autofluorescence and hemoglobin absorption are minimal in the 650-900 nm window. Cy5-labeled DNA on nanoparticles can be detected through several millimeters of tissue in mice following intravenous injection. Liver and spleen accumulation (characteristic of most nanoparticle formulations) is readily visualized, as is tumor accumulation when the enhanced permeability and retention (EPR) effect or active targeting mechanisms are operative. Quantitative biodistribution is performed by ex vivo organ fluorescence imaging or by homogenizing organs and quantifying fluorescence intensity against a standard curve. For more precise pharmacokinetic data, the fluorescent readout should be correlated with quantitative PCR detection of the oligonucleotide payload or with inductively coupled plasma mass spectrometry (ICP-MS) for gold-containing constructs.

BOC Sciences provides custom synthesis and fluorescent labeling services for nucleic acid-nanoparticle conjugates used in drug delivery, theranostic, and biodistribution studies. Our capabilities span oligonucleotide modification with thiol, amine, azide, or alkyne handles, fluorophore labeling with visible to near-infrared dyes, and purification and analytical characterization of nanoparticle-nucleic acid conjugates.